Loading...
ROCO
6461
Market cap100mUSD
Oct 08, Last price  
29.20TWD
1D
0.00%
1Q
12.09%
Jan 2017
-45.93%
IPO
-76.72%
Name

Intech Biopharm Ltd

Chart & performance

D1W1MN
ROCO:6461 chart
P/E
—
P/S
29.93
EPS
—
Div yield, %
—
Shrs. gr., 5y
-1.97%
Rev. gr., 5y
38.49%
Revenues
108m
+170.31%
021,106,00038,899,00023,647,00025,847,00039,779,000107,527,000
Net income
-389m
L+5.66%
0-250,370,000-301,756,000-327,877,000-337,987,000-368,207,000-389,032,000
CFO
-361m
L+34.14%
-189,094,000-167,378,000-200,606,000-190,389,000-232,085,000-269,216,000-361,132,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Intech Biopharm Corporation is a pharmaceutical company dedicated to the global development and production of generic medications for respiratory conditions. Their portfolio includes innovative drug delivery systems, such as iLEF (inhaled low ethanol formulation), a proprietary metered dose inhaler platform specifically engineered for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Additionally, they offer a dry powder inhaler (DPI) technology, which utilizes blisters and capsules for precise dosage. These therapeutic solutions are marketed under various brand names, including SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011. Established in Taipei, Taiwan, in 2010, the company maintains its headquarters in the city.

Key people

Chairman of the Board · since 2017
General Manager · since 2025
Guoxiong Wu
Deputy General Manager · since 2017
Shuhui Chen
Senior Manager of Accounting, Corporate Governance Officer · since 2024
Chi-Ying Huang
Director · since 2023
Director · since 2022
Director · since 2025
Director · since 2021
Tzyy-Po Wang
Director · since 2026
Yumei Xue
Director · since 2020
Fangping Chen
Independent Director · since 2017
Dequan Fan
Independent Director · since 2015
Xiumei Lin
Independent Director · since 2015
IPO date
Jul 15, 2014
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT